ARDX Ardelyx Inc.

5.90
+0.05  (1%)
Previous Close 5.85
Open 5.85
Price To book 2.61
Market Cap 280456376
Shares 47,534,979
Volume 84,342
Short Ratio 4.67
Av. Daily Volume 1,160,065

SEC filingsSee all SEC filings

  1. 8-K - Current report 171250172
  2. 8-K - Current report 171224069
  3. 8-K - Current report 171215360
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181044
  5. 8-K - Current report 171181032

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released October 11, 2017. Primary endpoint met but with relatively high rates of diarrhea. NDA filing due 2H 2018.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
RDX7675
Hyperkalemia
Phase 3 trial initiation announced January 3, 2017.
RDX227675
Hyperkalemia
Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial initiation due following feedback from FDA.
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
  2. Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
  3. 5 Affordable Breakout Stocks Offering Excellent Returns
  4. Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers
  5. Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers
  6. Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
  7. Ardelyx reports 3Q loss
  8. Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
  9. Growth Stocks Investors Love
  10. H.C. Wainwright Pounds the Table on Synergy Pharmaceuticals Inc (SGYP)
  11. Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
  12. 3 Biotech Stocks That Soared This Week: Are They Buys?
  13. Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Ardelyx Inc.
  14. Why Ardelyx Inc Skyrocketed Higher Today
  15. Why Spartan Motors, Ardelyx, and Glu Mobile Jumped Today
  16. Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up
  17. Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers
  18. Ardelyx jumps more than 60% after positive study results
  19. Ardelyx's irritable bowel syndrome drug succeeds in trial
  20. Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

SEC Filings

  1. 8-K - Current report 171250172
  2. 8-K - Current report 171224069
  3. 8-K - Current report 171215360
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181044
  5. 8-K - Current report 171181032
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 171171100
  7. 8-K - Current report 171132764
  8. 8-K - Current report 171090432
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 171063076
  10. 8-K - Current report 171052679